Liver Cancer News and Research

RSS

Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.

Study: Capecitabine with concurrent radiation is effective for treating gastric cancer

Gastric cancer is a major cause of cancer deaths in the world. The outcome of large gastric tumors and those with lymph node involvement remains poor after surgical resection. The optimal adjuvant therapy after surgical resection remains to be determined.

21 Sep 2010

Professor named recipient of 2010 Phoenix Award Glass Person of the Year

Dr. Delbert Day, Curators' Professor emeritus of materials science and engineering at Missouri University of Science and Technology, has been named the 2010 Phoenix Award Glass Person of the Year, the glass industry's top honor. The Phoenix Award is given annually to a living person who has made outstanding contributions to the industry.

16 Sep 2010

AAPCHO launches campaign to raise chronic hepatitis B awareness

The U.S. Department of Health and Human Services' Office of Minority Health, the Hepatitis B Foundation and the Association of Asian Pacific Community Health Organizations (AAPCHO) today launched a new campaign to raise awareness of the epidemic of chronic hepatitis B among Americans of Asian and Pacific Islander heritage.

15 Sep 2010

Provectus completes enrollment in first cohort of PV-10 Phase 1 trial for liver cancer

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that it has completed enrollment in the first of two dose cohorts in its Phase 1 clinical trial of PV-10 for liver cancer, and that the therapy was very well tolerated by all three subjects treated, with substantial evidence of efficacy.

15 Sep 2010

High dose peretinoin reduces recurrence of HCC after surgical resection or ablation in HCV positive patients

Kowa Company, Ltd. announced today that the results of a Phase II/III trial showed that high dose peretinoin (NIK-333) given daily for up to 96 weeks reduced the recurrence of hepatocellular carcinoma (HCC) after surgical resection or ablation in hepatitis C virus (HCV) positive patients when compared to placebo.

13 Sep 2010

Merit Medical Systems acquires BioSphere Medical

Merit Medical Systems, Inc. today announced the completion of its acquisition of BioSphere Medical, Inc., a leading developer and marketer of embolotherapeutic products for the treatment of uterine fibroids, hypervascularized tumors, and arteriovenous malformations.

13 Sep 2010

Jennerex reports positive interim data from trial of JX-594 and sorafenib for liver cancer

Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today reported positive interim data from a pilot trial using JX-594 followed by sorafenib (Nexavar®) to treat liver cancer patients. The data were presented today at the Fourth Annual International Liver Cancer Association Conference in Montreal, Canada.

13 Sep 2010

Study finds Laotian/Hmong-Americans have low survival rates for liver cancer

Among Asian-Americans living in California, Laotian/Hmong-Americans have the lowest survival rates for the most common type of liver cancer, a new study by researchers with the UC Davis School of Medicine has found.

10 Sep 2010

UC San Diego proferssor awarded 2010 Harvey Prize in human health by Technion

Michael Karin, PhD, Distinguished Professor of Pharmacology and Pathology at the University of California, San Diego School of Medicine has been awarded the 2010 Harvey Prize in human health by the Technion, Israel's premier institute of technology.

9 Sep 2010

Phase 3 REALIZE study shows milestone in treatment development for hepatitis C

Vertex Pharmaceuticals Incorporated today announced that 65% of people overall achieved a sustained viral response (SVR or viral cure) with a telaprevir-based regimen in the pivotal Phase 3 REALIZE study, as compared to 17% of people in the control arm who received pegylated-interferon and ribavirin alone.

8 Sep 2010

Onyx enters commercialization agreement with Ono for carfilzomib and ONX 0912 development program

Onyx Pharmaceuticals, Inc. today announced that it has entered into an exclusive agreement with Ono Pharmaceutical Co., Ltd. to develop and commercialize two compounds from Onyx's proteasome inhibitor development program, carfilzomib and ONX 0912. Under the terms of the agreement, Ono has exclusive rights to develop and commercialize both compounds for all oncology indications in Japan.

8 Sep 2010

Jennerex, Transgene enter partnership to develop JX-594 product for tumor treatment

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene Euronext, a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that they have entered into an exclusive partnership to develop and commercialize JX-594 for the treatment of solid tumors in Europe, the Commonwealth of Independent States (CIS) and the Middle East.

8 Sep 2010

BioAlliance Pharma receives European patent for acyclovir Lauriad tablets for recurrent herpes labialis

BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, today announced the grant of a European patent protecting its product acyclovir Lauriad.

8 Sep 2010

Researchers complete INX-189 clinical trials for Hepatitis C virus

The first clinical trials on a new investigational drug being developed to treat infections caused by Hepatitis C virus have been successfully completed.

3 Sep 2010

Abbott RealTime HBV assay receives marketing approval from FDA

Abbott announced today it has received approval from the U.S. Food and Drug Administration to market the Abbott RealTime HBV assay for measuring viral load or the amount of hepatitis B virus in a patient's blood. It is the first and only approved test capable of automating HBV viral load testing from sample extraction to final results.

2 Sep 2010

China PharmaHub signs distribution agreement for radioactive glass sphere treatment for liver cancer

China PharmaHub Corp. ("PharmaHub"), which has recently merged with World Wide Relics which has changed its name to China PharmaHub Corp, and is in the process of obtaining approval from FINRA to trade under its new name with a new symbol, announced today that it has signed an Exclusive Distribution Agreement ("Agreement") with a world leader in precision glass technology which can be utilized to manufacture high precision radioactive glass spheres that emit alpha, beta or gamma radiation, either individually or in combination, for the treatment of malignant tumors of the liver.

26 Aug 2010

FDA grants Fast Track Designation to Celsion's ThermoDox for liver cancer treamtment

Celsion Corporation, a leading oncology drug development company, today announced that the U.S. Food and Drug Administration has designated the HEAT Study of its investigational drug, ThermoDox, in combination with radiofrequency ablation, as a Fast Track Development Program.

25 Aug 2010

BioAlliance Pharma launches Oravig drug in the U.S. market

BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, today announces the launch in the United States of Oravig® (known as Loramyc® in Europe) for the treatment of oropharyngeal candidiasis (OPC) in adults by its commercial partner, Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc..

25 Aug 2010

Long-term entecavir therapy suppresses HBV DNA, normalizes ALT and improves liver histology

Researchers from this international study found that patients with chronic hepatitis B virus (HBV) infection who received at least 3 years of cumulative entecavir (antiviral) therapy achieved substantial histologic improvement and regression of fibrosis or cirrhosis. Full details of the study appear in the September issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD).

18 Aug 2010

Long-term Entecavir therapy reverses fibrosis and cirrhosis in chronic hepatitis B patients

17 Aug 2010

Liver Cancer News and Research

Further Reading

Study: Capecitabine with concurrent radiation is effective for treating gastric cancer

Professor named recipient of 2010 Phoenix Award Glass Person of the Year

AAPCHO launches campaign to raise chronic hepatitis B awareness

Provectus completes enrollment in first cohort of PV-10 Phase 1 trial for liver cancer

High dose peretinoin reduces recurrence of HCC after surgical resection or ablation in HCV positive patients

Merit Medical Systems acquires BioSphere Medical

Jennerex reports positive interim data from trial of JX-594 and sorafenib for liver cancer

Study finds Laotian/Hmong-Americans have low survival rates for liver cancer

UC San Diego proferssor awarded 2010 Harvey Prize in human health by Technion

Phase 3 REALIZE study shows milestone in treatment development for hepatitis C

Onyx enters commercialization agreement with Ono for carfilzomib and ONX 0912 development program

Jennerex, Transgene enter partnership to develop JX-594 product for tumor treatment

BioAlliance Pharma receives European patent for acyclovir Lauriad tablets for recurrent herpes labialis

Researchers complete INX-189 clinical trials for Hepatitis C virus

Abbott RealTime HBV assay receives marketing approval from FDA

China PharmaHub signs distribution agreement for radioactive glass sphere treatment for liver cancer

FDA grants Fast Track Designation to Celsion's ThermoDox for liver cancer treamtment

BioAlliance Pharma launches Oravig drug in the U.S. market

Long-term entecavir therapy suppresses HBV DNA, normalizes ALT and improves liver histology

Long-term Entecavir therapy reverses fibrosis and cirrhosis in chronic hepatitis B patients

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News